Sabino Ciavarella

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9295062/publications.pdf

Version: 2024-02-01

21	463	567144 15	752573 20
papers	citations	h-index	g-index

23	23	23	983
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mesenchymal Stem Cells: A New Promise in Anticancer Therapy. Stem Cells and Development, 2011, 20, 1-10.	1.1	47
2	In vitro antiâ€myeloma activity of <scp>TRAIL</scp>â€expressing adiposeâ€derived mesenchymal stem cells. British Journal of Haematology, 2012, 157, 586-598.	1.2	46
3	Immature dendritic cells in multiple myeloma are prone to osteoclastâ€like differentiation through interleukinâ€17<scp>A</scp> stimulation. British Journal of Haematology, 2013, 161, 821-831.	1.2	42
4	Umbilical Cord Mesenchymal Stem Cells: Role of Regulatory Genes in Their Differentiation to Osteoblasts. Stem Cells and Development, 2009, 18, 1211-1220.	1.1	41
5	Targeted Therapies in Cancer. BioDrugs, 2010, 24, 77-88.	2.2	36
6	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation inÂvitro. Experimental Hematology, 2011, 39, 773-783.e1.	0.2	33
7	Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells. Annals of the New York Academy of Sciences, 2009, 1173, 449-457.	1.8	29
8	Boneâ€Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. Oncologist, 2009, 14, 264-275.	1.9	26
9	Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. Cellular Signalling, 2013, 25, 1108-1117.	1.7	21
10	A Peculiar Molecular Profile of Umbilical Cord-Mesenchymal Stromal Cells Drives Their Inhibitory Effects on Multiple Myeloma Cell Growth and Tumor Progression. Stem Cells and Development, 2015, 24, 1457-1470.	1.1	21
11	u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progression. BMC Cancer, 2017, 17, 215.	1.1	20
12	A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model. Biology of Blood and Marrow Transplantation, 2018, 24, 608-613.	2.0	19
13	Improving Provision of Care for Long-term Survivors of Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e1-e9.	0.2	17
14	Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells. BMC Cancer, 2015, 15, 692.	1.1	16
15	Cell Fusion and Hyperactive Osteoclastogenesis in Multiple Myeloma. Advances in Experimental Medicine and Biology, 2011, 714, 113-128.	0.8	15
16	A New Ensemble Method for Detecting Anomalies in Gene Expression Matrices. Mathematics, 2021, 9, 882.	1.1	12
17	Improvements in haematology for home health assistance and monitoring by a web based communication system. , 2016, , .		7
18	NR1H3 (LXRÎ±) is associated with proâ€inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large bâ€cell lymphoma. Hematological Oncology, 2022, 40, 864-875.	0.8	7

#	Article	IF	Citations
19	Cytotherapies in multiple myeloma: a complementary approach to current treatments?. Expert Opinion on Biological Therapy, 2013, 13, S23-S34.	1.4	4
20	Cell Fusion in Myeloma Marrow Microenvironment: Role in Tumor Progression. Critical Reviews in Oncogenesis, 2013, 18, 75-95.	0.2	2
21	Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic Review by the Fondazione Italiana Linfomi. Cancers, 2022, 14, 519.	1.7	2